|
07 Oct 2022 |
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
|
|
07 Oct 2022 |
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
|
|
05 Oct 2022 |
Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma
|
|
04 Oct 2022 |
Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
|
|
03 Oct 2022 |
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
|
|
01 Oct 2022 |
Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting
|
|
30 Sep 2022 |
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
|
|
30 Sep 2022 |
BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA
|
|
30 Sep 2022 |
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
|
|
29 Sep 2022 |
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
|
|
28 Sep 2022 |
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
|
|
27 Sep 2022 |
Immunotherapy: Tollys presents new data at OTS 2022, demonstrating anti-tumor activity of TL-532
|
|
27 Sep 2022 |
Atamyo Therapeutics Announces First Patient Dosed with ATA-100 Gene Therapy in LGMD-R9 Clinical Trial
|
|
26 Sep 2022 |
CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy
|
|
26 Sep 2022 |
Pfizer and Sangamo therapeutics announce phase 3 trial of investigational gene therapy for hemophilia a has re-opened recruitment
|
|
23 Sep 2022 |
Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
|
|
22 Sep 2022 |
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
|
|
21 Sep 2022 |
Persephone Biosciences Announces First Participant Enrolled in the ARGONAUT Study of Gut Microbiome-Linked Immune Modulation in Cancer Treatment Response
|
|
21 Sep 2022 |
Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0803 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
|
|
21 Sep 2022 |
Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology
|
|
21 Sep 2022 |
CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit
|
|
21 Sep 2022 |
Immunis Initiates Patient Enrollment for Muscle Atrophy Phase 1/2a Clinical Trial
|
|
21 Sep 2022 |
Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO
|
|
21 Sep 2022 |
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease
|
|
21 Sep 2022 |
Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110™, a KIR-CAR T Cell Immunotherapy Candidate
|
